Oncology Advancements Accelerate Amid Rising Early-Onset Cancer Diagnoses

USA News Group Commentary
Issued on behalf of Oncolytics Biotech Inc.

VANCOUVER, BC, Dec. 20, 2024 /CNW/ -- USA News Group News Commentary – The American Cancer Society has published its Advances in Oncology – 2024 Research Highlights, underscoring major strides in cancer research and ongoing innovation. However, the optimism is tempered by a troubling finding: a significant global rise in early-onset colorectal cancer cases. This unsettling trend comes as the medical community grapples with the lingering effects of the COVID-19 pandemic. A recent Nature article revealed how disruptions in cancer care—particularly delays in screenings, diagnoses, and treatments—have likely exacerbated the progression of advanced disease, diminished survival rates, and complicated long-term data analysis. Still, the oncology field continues to push forward with promising developments emerging from key innovators like Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC.TO), Cardiff Oncology, Inc. (NASDAQ:CRDF), Personalis, Inc. (NASDAQ:PSNL), Tempus AI, Inc. (NASDAQ:TEM), and Checkpoint Therapeutics, Inc. (NASDAQ:CKPT).